You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
In-situ gelling controlled release injection of rivastigmine to treat Alzheimers disease
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-FDP-024
- By: SAIF, Alasoul (King abdulaziz university, Saudi Arabia)
- Co-author(s): Rawan othman Almadfaa: pharmacy, king abdulaziz university, jeddah, Saudi Arabia
Alasoul Saif: pharmacy, king abdulaziz university, jeddah,Saudi Arabia
Hatoun labban:pharmacy, king abdulaziz university, jeddah,Saudi Arabia - Abstract:
Background
Alzheimer is a neurodegenerative disease that is characterized by deterioration of cognitive & memory functions. Rivastigmine (RIV) is one of the most common drugs available for the treatment. The main challenge for its use is the frequent dosing and compliance to medications. As a result, Alzheimer's patients stop taking rivastigmine
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026